Clinical trials can play an important role in the treatment of ductal carcinoma in situ. At present, researchers are investigating a number of promising therapies, ranging from new chemotherapy drugs to targeted hormonal treatments. These treatments have the potential to produce better outcomes than current options or produce fewer side effects; if a clinical trial confirms either of these scenarios, the new treatment may eventually be recommended for use in a wider range of settings.
Through ductal carcinoma in situ clinical trials, researchers have the ability to:
- Compare the effectiveness of two or more therapies
- Identify the patients who are most likely to benefit from a specific treatment; e.g., a patient whose tumors are hormone-receptor-positive may benefit from a new hormone-based therapy
- Determine the best dosing options for a specific medication
- Evaluate the side effects of a new treatment and determine the best ways to manage them
At the same time, participants have the ability to access some of the most innovative breast cancer treatment options. For ductal carcinoma in situ, these treatments might include hormone-based therapies that could help reduce the risk of a recurrence, along with more targeted radiation therapy techniques that could minimize radiation exposure to healthy breast tissues.
At Moffitt Cancer Center, clinical trials are one of our major points of emphasis. We have been named a National Cancer Institute-designated Comprehensive Cancer Center for our efforts, which have included a number of studies focusing specifically on early-stage breast cancer treatments.
Individuals who are interested in our ductal carcinoma in situ clinical trials do not need to obtain physician referrals to participate. Call 1-813-745-6100 or 1-800-679-0775(toll-free) or submit a clinical trials inquiry form.